EGFR Ki-67在含微乳头结构肺腺癌中的表达及临床相关性分析

doi:10.3969/j.issn.1006-6233.2018.06.001

Abstract
Figure/Table
References
Related Citation (6)

Download: PDF (1339 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the relationship between epidermal growth factor receptor (EGFR) gene mutation and the expression of Ki-67 protein in lung adenocarcinoma with micropapillary structure (MPP) and its clinical significance. Methods: The clinical data of MPP lung adenocarcinoma in our hospital from 2013 to 2017 were collected. The mutation of EGFR gene in 80 patients was detected by gene sequencing, and the expression of Ki67 was detected by immunohistochemistry.Results: Of the 80 specimens, 50 cases were detected EGFR mutation, the total detection rate was 62.5%. Among them, the mutation rate of EGFR gene was high in non smoking and female. It was not related to age, tumor size, metastasis and staging; the expression rate of Ki67 protein was 63.8%. The expression of Ki67 and sex, age, smoking history, tumor size, lymph node metastasis and staging were all. No correlation; EGFR and Ki67 expression were positively correlated. Conclusion: The mutation rate of EGFR in MPPAC is higher than that in other subtypes of lung adenocarcinoma. It is highly expressed in female, non smoking, tumor size over 3cm. The expression rate of Ki67 in MPPAC was higher than that in other subtypes of lung adenocarcinoma, and it was highly expressed in patients with tumor diameter greater than 3cm. In MPPAC, the expression of EGFR gene and Ki67 protein is positively correlated. The positive rate of both of them is related to the size of tumor. It is speculated that the mutation of EGFR gene leads to abnormal overexpression of Ki67 and promotes the proliferation of tumor cells. In the Sanya group with different MPP ratios, the EGFR gene mutation rate and the positive rate of Ki67 protein expression were not related to the proportion of MPP.

Key words： Micropapillary lung adenocarcinoma EGFR Gene mutation Ki67

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.06.001 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I6/881

[1] Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015. [J]. Lung Cancer,2016,66(2):115~132.
[2] Yoshizawa A,Motoi N,Riely GJ,et a1.Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma:prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases[J].Mod Pathol,201l,4(5):653~654.
[3] Amin MB,Tamboli P,Merchant SH,et a1.Micmpapillary component In lung adenoeareinoma:a distinctive histologic feature with possible prognostic significance[J].Am Surg Pathol,2002,26(3):358~364.
[4] Cavarga I,Kocan P,Boor A,et al.Immunohistochemical markets of proliferation and vascularisation in preneoplastic bronchial lesions and invasive non-small cell lung cancer[J].Neoplasma,2009,56(5):414~421.
[5] Russell PA,Wainer Z,wright GM,et a1.Does lung adenocarcinoma subtype predict patient survival:A elinicopathologic study based on the new Intemational Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international muhidisciplinary lung adenocarcinoma classification [J].Thorac Oncol,2011,6(9):1496~1504.
[6] Warth A, Penzel R, Lindenmaier H, et al. EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype[J].Eur Respir, 2014, 43(3): 872~883.
[7] Chao L, Yi-Sheng H, Yu C, et al. Relevance of EGFR mutation with micropapillary pattern according to the novel IASLC/ATS/ERS lung adenocarcinoma classification and correlation with prognosis in Chinese patients[J].Lung Cancer, 2014, 86(2): 164~169.
[8] Yang JJ, Chen HJ, Yan HH, et al. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer[J].Lung Cancer, 2013, 79(1): 33~39.
[9] Sumiyoshi S, Yoshizawa A, Sonobe M, et al. Pulmonary adenocarcinomas with micropapillary component significantly correlate with recurrence, but can be well controlled with EGFR tyrosine kinase inhibitors in the early stages[J].Lung Cancer, 2013, 81(1): 53~59.
[10] Lin C, Chen X, Li M, et al. Programmed death-ligand 1 expression predicts tyrosine kinase inhibitor response and better prognosis in a cohort of patients with epidermal growth factor receptor mutation-positive lung adenocarcinoma[J]. Clinical Lung Cancer, 2015, 16(5): e25~e35.
[11] Kim C H, Lee H S, Park J H, et al. Prognostic role of p53 and Ki-67 immunohistochemical expression in patients with surgically resected lung adenocarcinoma: a retrospective study[J]. Journal of Thoracic Disease, 2015, 7(5): 822.